Compare CNVS & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | CVM |
|---|---|---|
| Founded | 2000 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 53.1M |
| IPO Year | 2003 | 1987 |
| Metric | CNVS | CVM |
|---|---|---|
| Price | $2.41 | $6.47 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 136.2K | 57.1K |
| Earning Date | 11-14-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $79,791,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $36.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 77.29 | N/A |
| 52 Week Low | $2.24 | $1.98 |
| 52 Week High | $7.39 | $32.70 |
| Indicator | CNVS | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 42.51 |
| Support Level | $2.40 | $5.56 |
| Resistance Level | $2.61 | $6.69 |
| Average True Range (ATR) | 0.16 | 0.54 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 29.20 | 36.16 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.